Sciex acquires Intabio
Sciex has acquired Intabio, developer of the Blaze system for biotherapeutic analysis and quality assessment. The Blaze system enables direct coupling of imaged capillary isoelectric focusing for charge variant analysis with high-resolution mass spectrometry to detect intact proteins. Read More
FDA issues COVID-19 guidance for cell and gene therapy manufacturers
The U.S. Food and Drug Administration (FDA) published new guidance this week regarding manufacturing consideration for cell and gene therapy products during COVID-19. Read More
Top biopharma companies form data exchange nonprofit
Ten of the world's largest biopharmaceutical companies publicly launched a new nonprofit corporation, Accumulus Synergy. The aim is to support interactions between industry and global health authorities to enable real-time collaboration and data exchange. Read More
XBiotech COVID-19 antibody therapy targets emerging virus strain
XBiotech has reported that its investigational True Human COVID-19 antibody therapy appears to be effective for the highly contagious strain of the SARS-CoV-2 virus that has emerged in the U.K. Read More
Northway Biotech christens new manufacturing plant in Boston area
Contract development and manufacturing organization Northway Biotech officially opened its new manufacturing site in the greater Boston area on January 21. Read More
Codiak BioSciences validates its engineered exosomes platform
Codiak BioSciences has published a new manuscript in the Journal of Molecular Therapy that identifies and characterizes two novel exosome-associated proteins using the company's proprietary engEx platform. Read More
Science 37 launches CRO program for decentralized clinical trials
Science 37 has launched a partnership program called Science 37 Certified, which is designed to empower contract research organizations (CROs) with access, training, and commercial support required to deliver decentralized clinical studies for pharmaceutical sponsors. Read More
Kuur provides positive interim clinical data for CAR-NKT cell therapy programs
Kuur Therapeutics has released results from phase I clinical trials evaluating its off-the-shelf chimeric antigen receptor natural killer T (CAR-NKT)-cell immunotherapy candidates in relapsed/refractory neuroblastoma and CD19-positive malignancies. Read More
VBI provides COVID-19 vaccine updates amid supply chain delays
VBI Vaccines has provided preclinical updates on its two COVID-19 vaccine programs: VBI-2901, a trivalent pan-coronavirus vaccine candidate, and VBI-2902, a monovalent vaccine candidate expressing the SARS-CoV-2 spike protein. Read More
FDA commissioner Hahn leaves agency
Dr. Stephen Hahn, the commissioner of the U.S. Food and Drug Administration (FDA), has left the agency. He is being replaced on an interim basis by longtime FDA regulator Dr. Janet Woodcock. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
